High-throughput bioengineering technologies for vision restoration

用于视力恢复的高通量生物工程技术

基本信息

批准号：
9752542
负责人：
Sai Hemanth Chavala
金额：
$ 36.5万
依托单位：
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-09-30 至 2020-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9752542
关键词：
Age related macular degeneration Biological Assay Biomedical Engineering Blindness Bypass Cadaver Cardiac Myocytes Cell Culture Techniques Cell physiology Cells Chronic Clinical Clinical Trials Clone Cells Derivation procedure Development Disadvantaged Electrophysiology (science)Electroretinography Embryo Engineering FDA approved Fibroblasts Genetic Goals Growth Hepatocyte Heterogeneity Human Immune Immunosuppression Knowledge Laboratories Lead Libraries Macular degeneration Membrane Potentials Methods Modeling Modification Molecular Mus Neurons Nonexudative age-related macular degeneration Patients Phagocytosis Pharmaceutical Preparations Phenotype Phototransduction Pluripotent Stem Cells Politics Process Protocols documentation Rattus Replacement Therapy Reporter Retinal Retinal Degeneration Risk Secondary to Skin Small Molecule Chemical Library Source Structure of retinal pigment epithelium Subfamily lentivirinae Technology Testing Therapeutic Uses Time Tumorigenicity Vision cDNA Library cell type clinical candidate cytokine embryonic stem cell epigenome experimental study fetal high throughput screening human embryonic stem cell implantation improved induced pluripotent stem cell insight nerve stem cell non-invasive imaging novel photoreceptor degeneration preservation prevent public health relevance restoration retinal damage screening side effect small molecule libraries stem cell differentiation transcription factor transdifferentiation tumor visual cycle voltage

Age related macular degeneration Biological Assay Biomedical Engineering Blindness Bypass Cadaver Cardiac Myocytes Cell Culture Techniques Cell physiology Cells Chronic Clinical Clinical Trials Clone Cells Derivation procedure Development Disadvantaged Electrophysiology (science)Electroretinography Embryo Engineering FDA approved Fibroblasts Genetic Goals Growth Hepatocyte Heterogeneity Human Immune Immunosuppression Knowledge Laboratories Lead Libraries Macular degeneration Membrane Potentials Methods Modeling Modification Molecular Mus Neurons Nonexudative age-related macular degeneration Patients Phagocytosis Pharmaceutical Preparations Phenotype Phototransduction Pluripotent Stem Cells Politics Process Protocols documentation Rattus Replacement Therapy Reporter Retinal Retinal Degeneration Risk Secondary to Skin Small Molecule Chemical Library Source Structure of retinal pigment epithelium Subfamily lentivirinae Technology Testing Therapeutic Uses Time Tumorigenicity Vision cDNA Library cell type clinical candidate cytokine embryonic stem cell epigenome experimental study fetal high throughput screening human embryonic stem cell implantation improved induced pluripotent stem cell insight nerve stem cell non-invasive imaging novel photoreceptor degeneration preservation prevent public health relevance restoration retinal damage screening side effect small molecule libraries stem cell differentiation transcription factor transdifferentiation tumor visual cycle voltage

展开

项目摘要

DESCRIPTION (provided by applicant): Retinal degenerations collectively represent the leading cause of irreversible vision loss worldwide, and there is no FDA approved treatment to replace damaged retinal cells. Our long-term goal is to identify a safe and efficient method to generate RPE replacement cells. The hypothesis of this proposal is that a combination of defined factors can covert fibroblasts into functional iRPE. The Aims of this proposal are to 1) Utilize high-throughput assays to comprehensively screen a transcription factor library and small molecule library for candidates that can convert fibroblasts into RPE replacement cells and 2) determine if RPE replacement cells perform similarly to authentic RPE cells.

描述（由申请人提供）：视网膜退化总体代表了全球不可逆视力丧失的主要原因，并且没有FDA批准的治疗方法可以替代受损的视网膜细胞。我们的长期目标是确定一种安全有效的方法来生成RPE替代单元。该提议的假设是，定义因子的组合可以将成纤维细胞掩盖为功能性IRPE。该提案的目的是1）使用高通量测定法对可以将成纤维细胞转换为RPE替换细胞的候选者进行全面筛选转录因子库和小分子库，并2）确定RPE替换细胞是否与正义RPE细胞相似。